{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kwok DW"],"funding":["NCI NIH HHS","NINDS NIH HHS","NIH HHS","NIGMS NIH HHS"],"pagination":["463-473"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11903331"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["639(8054)"],"pubmed_abstract":["T cell-based immunotherapies hold promise in treating cancer by leveraging the immune system's recognition of cancer-specific antigens<sup>1</sup>. However, their efficacy is limited in tumours with few somatic mutations and substantial intratumoural heterogeneity<sup>2-4</sup>. Here we introduce a previously uncharacterized class of tumour-wide public neoantigens originating from RNA splicing aberrations in diverse cancer types. We identified T cell receptor clones capable of recognizing and targeting neoantigens derived from aberrant splicing in GNAS and RPL22. In cases with multi-site biopsies, we detected the tumour-wide expression of the GNAS neojunction in glioma, mesothelioma, prostate cancer and liver cancer. These neoantigens are endogenously generated and presented by tumour cell"],"journal":["Nature"],"pubmed_title":["Tumour-wide RNA splicing aberrations generate actionable public neoantigens."],"pmcid":["PMC11903331"],"funding_grant_id":["P50 CA097257","R01 CA222965","R01 CA269733","R37 CA259177","P30 CA008748","T32 GM008568","T32 CA151022","R50 CA274229","R35 NS105068","S10 OD028511","P01 CA118816","R01 CA286507","P50 CA217694"],"pubmed_authors":["Diaz A","Liu J","Colton Cove M","Lakshmanachetty S","Saijo A","Barpanda A","Wu SH","Nejo T","Yamamichi A","Phillips JJ","Ogino H","Klebanoff CA","Hervey-Jumper SL","Chen LH","Kwok DW","Wiita AP","Costello JF","Watchmaker PB","Woo J","Chang SM","Chan GKL","Gallus M","Okada H","Jung J","Okada K","Hong C","Stevers NO","Du A","Etxeberria I","Grishanina NR","Ramos E"],"additional_accession":[]},"is_claimable":false,"name":"Tumour-wide RNA splicing aberrations generate actionable public neoantigens.","description":"T cell-based immunotherapies hold promise in treating cancer by leveraging the immune system's recognition of cancer-specific antigens<sup>1</sup>. However, their efficacy is limited in tumours with few somatic mutations and substantial intratumoural heterogeneity<sup>2-4</sup>. Here we introduce a previously uncharacterized class of tumour-wide public neoantigens originating from RNA splicing aberrations in diverse cancer types. We identified T cell receptor clones capable of recognizing and targeting neoantigens derived from aberrant splicing in GNAS and RPL22. In cases with multi-site biopsies, we detected the tumour-wide expression of the GNAS neojunction in glioma, mesothelioma, prostate cancer and liver cancer. These neoantigens are endogenously generated and presented by tumour cell","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-06-02T20:51:50.193Z","creation":"2025-04-03T23:56:43.295Z"},"accession":"S-EPMC11903331","cross_references":{"pubmed":["39972144"],"doi":["10.1038/s41586-024-08552-0"]}}